VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline (PRNewswire) - Jun 3, 2024 - "VGXI, Inc....has entered into a strategic partnership with Sutro Biopharma, Inc. (Sutro) to support clinical production of luveltamab tazevibulin, abbreviated as 'luvelta', a novel Folate Receptor-α (FRα)-targeting antibody-drug conjugate (ADC) with the potential to address the unmet need in several FRα-expressing cancers....VGXI will supply cGMP plasmids at 1500L production scale for use in Sutro's XpressCF cell-free expression system to manufacture luvelta. With evidence of clinical activity and the potential to benefit 8 out of 10 PROC patients, luvelta could address a high unmet medical need in patients with low to medium FRα expression."
Licensing / partnership • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor
|